Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016

Date: July 27, 2016
Pages: 184
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S551F1D44FDEN
Leaflet:

Download PDF Leaflet

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
  • The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects
  • The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Systemic Sclerosis (Scleroderma) Overview
Therapeutics Development
Pipeline Products for Systemic Sclerosis (Scleroderma) - Overview
Pipeline Products for Systemic Sclerosis (Scleroderma) - Comparative Analysis
Systemic Sclerosis (Scleroderma) - Therapeutics under Development by Companies
Systemic Sclerosis (Scleroderma) - Therapeutics under Investigation by Universities/Institutes
Systemic Sclerosis (Scleroderma) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Systemic Sclerosis (Scleroderma) - Products under Development by Companies
Systemic Sclerosis (Scleroderma) - Products under Investigation by Universities/Institutes
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
Allergan Plc
Angion Biomedica Corp.
Antitope Limited
Bayer AG
BioLineRx, Ltd.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Covis Pharmaceuticals, Inc.
CSL Limited
Cumberland Pharmaceuticals, Inc.
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
Fibrocell Science, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
iBio, Inc.
Inventiva
Kadmon Corporation, LLC
MedImmune, LLC
miRagen Therapeutics, Inc.
PDX Pharmaceuticals LLC
Peptinov SAS
ProMetic Life Sciences Inc.
Ribomic Inc.
Sanofi
Stemline Therapeutics, Inc.
Stratatech Corporation
Vida Therapeutics Inc.
VivaCell Biotechnology Espana S.L.
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
acALY-18 - Drug Profile
acetylcysteine - Drug Profile
ambrisentan - Drug Profile
ANG-3070 - Drug Profile
belimumab - Drug Profile
BL-1110 - Drug Profile
BOT-191 - Drug Profile
C-1889 - Drug Profile
C-82 - Drug Profile
Cell Therapy for Dermatology and Immunology - Drug Profile
CM-101 - Drug Profile
disitertide - Drug Profile
factor XIII (human) - Drug Profile
FCX-013 - Drug Profile
GKT-831 - Drug Profile
GSK-2330811 - Drug Profile
IBIOCFB-03 - Drug Profile
ifetroban sodium - Drug Profile
IVA-337 - Drug Profile
JBT-101 - Drug Profile
KD-025 - Drug Profile
M-10 - Drug Profile
MEDI-7734 - Drug Profile
MGN-4220 - Drug Profile
Monoclonal Antibodies to Inhibit IL-3RA for Autoimmune Disorders - Drug Profile
nintedanib - Drug Profile
nitroglycerin - Drug Profile
Oligonucleotide for Scleroderma - Drug Profile
onabotulinumtoxin A - Drug Profile
PAT-048 - Drug Profile
PBI-4050 - Drug Profile
PDX-002 - Drug Profile
PPV-06 - Drug Profile
RBM-006 - Drug Profile
riociguat - Drug Profile
RP-182 - Drug Profile
SAR-100842 - Drug Profile
SAR-317461 - Drug Profile
Small Molecule to Inhibit NFkB for Immunology and Oncology - Drug Profile
SRI-35241 - Drug Profile
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile
terguride - Drug Profile
tocilizumab - Drug Profile
VCE-0048 - Drug Profile
VEDA-1209 - Drug Profile
VTI-1000 Series - Drug Profile
Systemic Sclerosis (Scleroderma) - Dormant Projects
Systemic Sclerosis (Scleroderma) - Discontinued Products
Systemic Sclerosis (Scleroderma) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2016
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Antitope Limited, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by BioLineRx, Ltd., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by BiOrion Technologies B.V., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals, Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by CSL Limited, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Digna Biotech, S.L., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science, Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex S.A., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences, Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by iBio, Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corporation, LLC, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune, LLC, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by miRagen Therapeutics, Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics, Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corporation, H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by Vida Therapeutics Inc., H2 2016
Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana S.L., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2016
Systemic Sclerosis (Scleroderma) - Dormant Projects (Contd..1), H2 2016
Systemic Sclerosis (Scleroderma) - Dormant Projects (Contd..2), H2 2016
Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2016
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Allergan Plc
Angion Biomedica Corp.
Antitope Limited
Bayer AG
BioLineRx, Ltd.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Covis Pharmaceuticals, Inc.
CSL Limited
Cumberland Pharmaceuticals, Inc.
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
Fibrocell Science, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
iBio, Inc.
Inventiva
Kadmon Corporation, LLC
MedImmune, LLC
miRagen Therapeutics, Inc.
PDX Pharmaceuticals LLC
Peptinov SAS
ProMetic Life Sciences Inc.
Ribomic Inc.
Sanofi
Stemline Therapeutics, Inc.
Stratatech Corporation
Vida Therapeutics Inc.
VivaCell Biotechnology Espana S.L.
Skip to top


Ask Your Question

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: